Woman's
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Woman's sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Woman's: 17 sponsored US clinical trials, 3 recruiting.
Woman's sponsors 17 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 12 completed. 10 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Disorder of Glucose Regulation, with 1 trials.
Top-decile sponsor footprint
Woman's ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
17 total, page 1 of 1
Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy
NCT07287826
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
NCT04873050
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
NCT04047849
The PPCGMS Intervention After GDM Trial
NCT06057805
The CGMS in GDM Labor and Delivery Study
NCT05067075
Effectiveness of CGMS Vs. Self-monitoring Blood Glucose (SMBG) in Woman with Gestational Diabetes
NCT04948112
Ibuprofen Versus Indomethacin Following Emergent Cerclage Placement
NCT04726085
Use Of Nfant(R) Technology Feeding System For Infants Less Than 30 Weeks GA
NCT04256889
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
NCT03480022
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
NCT02635386
Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
NCT02338193
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
NCT02022007
Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
NCT01856907
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
NCT01234649
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
NCT01360996
Comprehensive Postpartum Screening Strategies for Women With Gestational Diabetes Mellitus (GDM)
NCT00849849
Insulin Action During Pregnancy in Woman at High Risk for Gestational Diabetes
NCT00687479
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 5 |
| Phase 4 | 5 |
Therapeutic Areas
Where Woman's enrollment is open (later-stage tilt)
3 recruiting of 17 indexed (18% open); 12 completed (71%).
Phase mix: 10 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Disorder of Glucose Regulation (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Woman's: open-pipeline peers nationwide
Peers matched on 17 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Woman's sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Endologix · 18% recruiting · 17 trials
- National Institute on Deafness and Other Communication Disorders (NIDCD) · 18% recruiting · 34 trials
- NICHD Pelvic Floor Disorders Network · 18% recruiting · 17 trials
- Sanford Health · 18% recruiting · 34 trials
Related
What to do with this Woman's page
17 registered trials is a research-attention snapshot, not an endorsement of Woman's or any single study.
- 3 of Woman's's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Disorder of Glucose Regulation is the condition Woman's studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Disorder of Glucose Regulation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Woman's pipeline card: 17 registered trials from official public datasets.Report a data error.